(19)
(11) EP 4 798 181 A1

(12)

(43) Date of publication:
02.09.2026 Bulletin 2026/36

(21) Application number: 24883236.2

(22) Date of filing: 23.10.2024
(51) International Patent Classification (IPC): 
A61K 31/13(2006.01)
A61K 31/33(2006.01)
 A61K 31/335(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/58
(86) International application number:
PCT/US2024/052539
(87) International publication number:
WO 2025/090589 (01.05.2025 Gazette 2025/18)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 24.10.2023 US 202363592627 P
23.02.2024 US 202463557269 P

(71) Applicant: Emmyon, Inc.
SW Rochester, MN 55902 (US)

(72) Inventor:
  • TALLEY, John
    St. Louis, Missouri 63109 (US)

(74) Representative: Schlich 
9 St Catherine's Road Littlehampton
West Sussex BN17 5HS
West Sussex BN17 5HS (GB)

   


(54) FUROSTAN-3-OL DERIVATIVES FOR THE TREATMENT OF OBESITY AND DIABETES